Renhe Pharmacy Co

Renhe Pharmacy Co FCF/Debt

The Free Cash Flow to Debt Ratio of Renhe Pharmacy Co (000650.SZ) as of Oct 28, 2026 is 14,381.48 %. In the previous year, Free Cash Flow to Debt Ratio was 1,691.73 % — a change of 750.11% (higher).

FCF/Debt

14,381.48 %

YoY

750.11%

Last updated:

Free Cash Flow to Debt Ratio of Renhe Pharmacy Co is 2024 14,381.48 % . Free Cash Flow to Debt Ratio of Renhe Pharmacy Co was 2023 1,691.73 % . It decreases by 750.11% higher compared to the previous year.

The Renhe Pharmacy Co FCF/Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF/Debt
Date
FCF/Debt
Jan 1, 2018
274,357.97 CNY
Jan 1, 2019
-743.91 CNY
Jan 1, 2020
1,013.23 CNY
Jan 1, 2021
812.86 CNY
Jan 1, 2022
3,052.16 CNY
Jan 1, 2023
1,691.73 CNY
Jan 1, 2024
14,381.48 CNY
The Renhe Pharmacy Co FCF/Debt history
YEARFCF/DebtYoY
14,381.48 %+750.11%
1,691.73 %-44.57%
3,052.16 %+275.49%
812.86 %-19.78%
1,013.23 %-236.20%
-743.91 %-100.27%
274,357.97 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Renhe Pharmacy Co Stock analysis

What does Renhe Pharmacy Co do? Renhe Pharmacy Co., Ltd. generates revenue through the manufacturing and distribution of pharmaceutical products including capsules, granules, tablets, powder, injections, suppositories, and ointment. The company operates in the domestic market, focusing on medical industrial manufacturing and medical merchandising. Its primary customers are domestic healthcare providers and retail outlets purchasing health-related products for distribution or direct consumer use. The firm's product portfolio spans various dosage forms essential for medical treatment and patient care. The company's business model relies on both wholesale and retail channels within China, serving the domestic pharmaceutical market. Renhe Pharmacy's manufacturing segment produces a wide range of medication forms, while its merchandising division handles the sale of health-related products. This dual approach allows the company to capture value across the pharmaceutical supply chain from production to consumer. Renhe Pharmacy Co., Ltd. serves the Chinese domestic market exclusively, with its operations centered on medical industrial manufacturing and medical merchandising. The company's revenue streams are derived from the sale of its diverse product range to healthcare institutions, pharmacies, and consumers through its retail network. This integrated approach ensures consistent market presence and customer reach within its geographic focus. Renhe Pharmacy Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Renhe Pharmacy Co stock

Free Cash Flow to Debt Ratio of Renhe Pharmacy Co is 14,381.48 % in 2024.

Free Cash Flow to Debt Ratio of Renhe Pharmacy Co changed from 1,691.73 % to 14,381.48 %, representing a 750.11% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow to Debt Ratio Renhe Pharmacy Co since 2006 – with annual values, charts, and detailed analysis.

FCF/Debt measures the percentage of total debt that could be repaid from free cash flow. It is a stricter measure than OCF/Debt as it accounts for capital expenditures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow to Debt Ratio's Renhe Pharmacy Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Renhe Pharmacy Co

All Key Metrics — Renhe Pharmacy Co